GSK (GSK) said Thursday that its phase 3 trial evaluating linerixibat as potential treatment for cholestatic pruritus, or relentless itch, in primary biliary cholangitis patients met the primary and key secondary endpoints.
The company said the trial met the primary endpoint of change from baseline in monthly itch score, with linerixibat significantly improving itch versus placebo over a 24-week period.
The trial also met key secondary endpoints, including "significant" improvements in itch score at week two and itch-related sleep interference over 24 weeks compared with placebo.
GSK also said the investigational drug's safety profile was consistent with data from previous studies.
GSK said linerixibat was granted orphan drug designation in cholestatic pruritus in PBC by the US Food and Drug Administration and European Medicines Agency.
Price: 36.70, Change: -0.48, Percent Change: -1.28
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。